AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine
In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models based on the classification of BRAF mutations. This panel covers all 3 classes of BRAF mutants, including subtypes for which viable therapeutic options remain limited. The authors demonstrate that these PDX models are responsive to BRAF and/or MEK inhibition.
Check out our comprehensive panel of PDX models
4988_A tailored platform enables BRAF-targeted drug discovery and precision medicine_final - Copy
Related Content
Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors...
VIEW RESOURCEMutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug,...
VIEW RESOURCE